5-Alpha reductase inhibitors in patients on active surveillance: Do the benefits outweigh the risk?
5-Alpha reductase inhibitors in patients on active surveillance: Do the benefits outweigh the risk? - Abstract
Prostate cancer (PCa) is a slow, progressive disease.
Prostate specific antigen testing, screening, and aggressive case identification has made PCa the most frequently diagnosed cancer. Concerns regarding overdiagnosis and overtreatment flourish on a large scale. In order to avoid overtreatment for those in whom therapeutic intervention is not required, active surveillance for eligible patients with the use of 5-alpha reductase can be considered a safe and a promising approach to delay the progression of the disease with minimal side effects.
Written by:
Al Edwan G, Fleshner N. Are you the author?
Division of Urology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada. [email protected]
Reference: Curr Urol Rep. 2013 Apr 12. Epub ahead of print.
doi: 10.1007/s11934-013-0324-y
PubMed Abstract
PMID: 23579402
Discussion Boards
- 118.9K All Discussion Boards
- 5 CSN Information
- 5 Welcome to CSN
- 118.9K Cancer specific
- 2.7K Anal Cancer
- 421 Bladder Cancer
- 297 Bone Cancers
- 1.6K Brain Cancer
- 28.1K Breast Cancer
- 374 Childhood Cancers
- 27.6K Colorectal Cancer
- 4.5K Esophageal Cancer
- 1.1K Gynecological Cancers (other than ovarian and uterine)
- 12.6K Head and Neck Cancer
- 6.1K Kidney Cancer
- 638 Leukemia
- 759 Liver Cancer
- 4K Lung Cancer
- 5K Lymphoma (Hodgkin and Non-Hodgkin)
- 212 Multiple Myeloma
- 7.1K Ovarian Cancer
- 31 Pancreatic Cancer
- 477 Peritoneal Cancer
- 5K Prostate Cancer
- 1.1K Rare and Other Cancers
- 519 Sarcoma
- 687 Skin Cancer
- 632 Stomach Cancer
- 189 Testicular Cancer
- 1.5K Thyroid Cancer
- 5.6K Uterine Cancer
- 6.2K Other Discussion Boards